Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Amplification”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)UnknownNCT04136600
What this trial is testing

EGFR Monoclonal Antibody for Advanced Gastric Cancer

Who this might be right for
Gastric CancerCetuximabNimotuzumab
Shanghai Changzheng Hospital 100
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Large-scale testing (Phase 3)Study completedNCT02573324
What this trial is testing

ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Who this might be right for
GlioblastomaGliosarcoma
AbbVie 691
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Early research (Phase 1)Looking for participantsNCT04429542
What this trial is testing

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal Cancer+8 more
Bicara Therapeutics 292
Testing effectiveness (Phase 2)Study completedNCT01520870
What this trial is testing

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Who this might be right for
GlioblastomaBrain Tumor, Recurrent
Grupo Español de Investigación en Neurooncología 49
Early research (Phase 1)Looking for participantsNCT06934889
What this trial is testing

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Who this might be right for
GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)UnknownNCT04880811
What this trial is testing

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 43
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Not applicableUnknownNCT06022276
What this trial is testing

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Who this might be right for
Solid TumorEGFR Amplification
Tianjin Medical University Second Hospital 46
Testing effectiveness (Phase 2)Study completedNCT03732352
What this trial is testing

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Who this might be right for
EGFR Gene AmplificationEGFR Gene MutationGlioblastoma+3 more
Jonsson Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT03888092
What this trial is testing

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Sunshine Lake Pharma Co., Ltd. 81
Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Load More Results